ATE531373T1 - Aromatische heterocyclische kondensierte indolobenzadiazepin-hcv-ns5b-inhibitoren - Google Patents

Aromatische heterocyclische kondensierte indolobenzadiazepin-hcv-ns5b-inhibitoren

Info

Publication number
ATE531373T1
ATE531373T1 AT09725965T AT09725965T ATE531373T1 AT E531373 T1 ATE531373 T1 AT E531373T1 AT 09725965 T AT09725965 T AT 09725965T AT 09725965 T AT09725965 T AT 09725965T AT E531373 T1 ATE531373 T1 AT E531373T1
Authority
AT
Austria
Prior art keywords
indolobenzadiazepine
aromatic heterocyclic
hcv ns5b
heterocyclic condensed
ns5b inhibitors
Prior art date
Application number
AT09725965T
Other languages
German (de)
English (en)
Inventor
John Bender
Zhong Yang
John Kadow
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE531373T1 publication Critical patent/ATE531373T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT09725965T 2008-03-27 2009-03-24 Aromatische heterocyclische kondensierte indolobenzadiazepin-hcv-ns5b-inhibitoren ATE531373T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3996108P 2008-03-27 2008-03-27
PCT/US2009/038010 WO2009120650A1 (en) 2008-03-27 2009-03-24 Aromatic heterocyclic fused indolobenzadiazepine hcv ns5b inhibitors

Publications (1)

Publication Number Publication Date
ATE531373T1 true ATE531373T1 (de) 2011-11-15

Family

ID=40810527

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09725965T ATE531373T1 (de) 2008-03-27 2009-03-24 Aromatische heterocyclische kondensierte indolobenzadiazepin-hcv-ns5b-inhibitoren

Country Status (10)

Country Link
US (1) US8431568B2 (enExample)
EP (1) EP2278977B1 (enExample)
JP (1) JP2011517673A (enExample)
KR (1) KR20100124848A (enExample)
CN (1) CN101980711B (enExample)
AT (1) ATE531373T1 (enExample)
AU (1) AU2009228451A1 (enExample)
ES (1) ES2374870T3 (enExample)
MX (1) MX2010010060A (enExample)
WO (1) WO2009120650A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103288828A (zh) * 2012-02-24 2013-09-11 中国科学院大连化学物理研究所 一种合成手性二氢-6H-吲哚并[2,1-c][1,4]-苯并二氮杂卓的方法
CN103539723A (zh) * 2013-10-29 2014-01-29 南方医科大学 一种3-氨基-2-芳甲酰基-1h-吲哚类衍生物的合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897392A (en) * 1989-07-03 1990-01-30 Hoechst-Roussel Pharmaceuticals, Inc. 4H-indolo(1,2-d)(1,2,4)triazolo(4,3-A)(1,4)benzodiazepines
DE602005013922D1 (de) * 2004-02-24 2009-05-28 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
AU2005298403A1 (en) 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
GB0518390D0 (en) * 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) * 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7521442B2 (en) 2006-05-25 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CN101490054B (zh) 2006-05-25 2012-05-16 百时美施贵宝公司 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
KR20090029827A (ko) * 2006-07-20 2009-03-23 제네랩스 테크놀로지스, 인코포레이티드 폴리사이클릭 바이러스 억제제
US7642251B2 (en) 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7652004B2 (en) 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143243B2 (en) 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8138171B2 (en) 2008-03-27 2012-03-20 Bristol-Myers Squibb Company Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors
US8133884B2 (en) 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C

Also Published As

Publication number Publication date
ES2374870T3 (es) 2012-02-22
MX2010010060A (es) 2010-09-30
WO2009120650A1 (en) 2009-10-01
KR20100124848A (ko) 2010-11-29
JP2011517673A (ja) 2011-06-16
AU2009228451A1 (en) 2009-10-01
EP2278977B1 (en) 2011-11-02
CN101980711A (zh) 2011-02-23
US20110014154A1 (en) 2011-01-20
CN101980711B (zh) 2012-10-31
EP2278977A1 (en) 2011-02-02
US8431568B2 (en) 2013-04-30

Similar Documents

Publication Publication Date Title
ATE469155T1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
ATE483712T1 (de) Hcv-ns5b-inhibitoren
DK2209789T3 (da) Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
EA201100390A1 (ru) Соединения для лечения гепатита с
WO2010030538A3 (en) Compounds for the treatment of hepatitis c
EA200901241A1 (ru) Соединения для лечения гепатита с
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
MX2012004032A (es) Compuestos para el tratamiento de hepatitis c.
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
MX2010008699A (es) Derivados heterociclicos como inhibidores de virus de la hepatitis c.
ATE494291T1 (de) Verbindungen zur behandlung von hepatitis c
EA201001275A1 (ru) Конформационно-ограниченные бифенильные производные для применения в качестве ингибиторов вируса гепатита с
EA200900676A1 (ru) Ингибиторы вируса гепатита с
CO6190510A2 (es) Inhibidores del virus de la hepatitis c
CO6400218A2 (es) Compuestos heterocíclicos antivirales
EA201071315A1 (ru) Ингибиторы протеазы вируса гепатита с
MX2012008443A (es) Nucleosidos antiviricos.
ATE551343T1 (de) Tetracyclische verbindungen zur behandlung von hepatitis c
ATE505473T1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
EA201001748A1 (ru) Соединения, используемые для лечения гепатита с
MX2010010061A (es) Compuestos para el tratamiento de hepatitis c.
EA201270798A1 (ru) Соединения для лечения гепатита с
MX2010010235A (es) Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a pirrolidina.